TABLE 2

Change from baseline to 14 days in fasting plasma biochemistry, liver enzymes, and urinary isoprostanes

PlaceboGW590735GW501516P (ANOVA)
n666
Glucose (mmol/l)−0.1 ± 0.1*−0.3 ± 0.2*−0.3 ± 0.2*0.25
Insulin (mU/l)1.2 ± 1.1*1.0 ± 1.9−1.7 ± 2.2*†‡0.01
HOMA-IR0.17 ± 0.18−0.02 ± 0.40−0.58 ± 0.53*†‡0.006
NEFA (μmol/l)22 ± 212−62 ± 90−247 ± 101†§0.01
Triglycerides (mmol/l)0.1 ± 0.7−0.4 ± 0.6−0.5 ± 0.4*0.16
Total cholesterol (mmol/l)−0.3 ± 0.5−0.6 ± 0.4*−1.0 ± 0.7*0.13
LDL cholesterol (mmol/l)−0.3 ± 0.4−0.6 ± 0.4*−0.9 ± 0.6*0.13
HDL cholesterol (mmol/l)−0.05 ± 0.080.07 ± 0.07*‖0.003 ± 0.070.049
ApoB (g/l)−0.06 ± 0.09−0.12 ± 0.06−0.20 ± 0.15*0.06
β-OH butyrate (μmol/l)8 ± 27−10 ± 37−19 ± 23*0.14
Urinary F2-isoprostanes (nmol · l−1 · mmol−1 creatinine)−0.02 ± 0.080.05 ± 0.10−0.10 ± 0.05§0.01
γ-GT (U/l)−3 ± 6−5 ± 3*−8 ± 60.11
AST (U/l)−1 ± 61 ± 20 ± 40.50
ALT (U/l)−3 ± 14−4 ± 14−13 ± 130.44

  • Data are means ± SD. P (ANOVA) describes the overall P value between groups.

  • *

    * P < 0.05, within-group change from baseline (paired t test);

  • †

    † P < 0.01, different from placebo (unpaired t test);

  • ‡

    ‡ P < 0.01, different from PPARα (unpaired t test);

  • §

    § P < 0.05, different from PPARα (unpaired t test);

  • P < 0.01, within-group change from baseline (paired t test);

  • ‖

    ‖ P < 0.05, different from placebo (unpaired t test).